Percheron Therapeutics

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In

Percheron Therapeutics (PER, formerly Antisense Therapeutics) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialise novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy, multiple sclerosis and acromegaly.

ANP has three products including ATL1102 injection for multiple sclerosis, ATL1103 injection for growth & sight disorders, and ATL1102 inhaled for asthma.

Contact Details

L30, Collins Place , 35 Collins Street Melbourne VIC 3000
03 9827 8999
percherontx.com

Lists and Charts

Share price

Share price

Percheron Therapeutics
Closing price for the last 90 trading days
View ASX Chart
Powered by Morningstar ®

Revenue

Company Share Transactions

  • Company Activity

    		 NEW ROLE: Anthony Filippis, 02 Oct 2023
    Gil Price
    		NEW ROLE: Gil Price, Consultant Medical Director, Non-Executive Director since 2021 11 Oct 2021
    		NEW ROLE: Alicia Mellors, Joint Company Secretary 29 Mar 2021
    Charmaine Gittleson
    		NEW ROLE: Charmaine Gittleson, Non-Executive Chair 29 Mar 2021
    		NEW ROLE: Nuket Desem, Director-Clinical & Regulatory Affairs 24 Nov 2020
    		NEW ROLE: George Tachas, Director Drug Discovery and Patents 24 Nov 2020
    Graham Mitchell
    		NEW ROLE: Graham Mitchell, Non-Executive Director 03 Nov 2020
    Gary Pace
    		NEW ROLE: Gary Pace, Non-Executive Director 03 Nov 2020
    		NEW ROLE: Robert Moses, Non-Executive Director, was Chair 2001-2021 03 Nov 2020

Related Information

Access to our data for Percheron Therapeutics is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Percheron Therapeutics is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today